HER2 alterations, including HER2 overexpression, gene amplification and gene mutations, are well established oncogenic drivers in NSCLC and are found in approximately 3% of all NSCLC cases, mostly adenocarcinomas53. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.